Active ingredientVemurafenibCat. No. P-V026-001CAS 918504-65-1Family · Pharmaceutical analytical standards
Vemurafenib
An inhibitor of the mutated BRAF kinase (V600E), approved in 2011 in the United States and in 2012 in Europe for advanced melanoma and, in the United States since 2017, also for Erdheim-Chester disease. This family brings together the active ingredient, labelled standards and other impurities.
Did you know?It was the first drug designed by fragment-based lead discovery to reach approval: the method starts from tiny molecular fragments that bind the target and grows them into a drug.
Go to the active ingredient →Active ingredientVemurafenibCat. No. P-V026-001CAS 918504-65-1
Isotopically labelledVemurafenib-d7Cat. No. P-V026-002CAS 1365986-73-7
ImpurityVemurafenib Impurity 1Cat. No. P-V026-003CAS 1262985-23-8
ImpurityVemurafenib Impurity 2Cat. No. P-V026-004CAS 1262985-30-7
ImpurityVemurafenib Impurity 3Cat. No. P-V026-005CAS 918504-34-4No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.